Related Experiment Video

Updated: Jun 20, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives

Brunangelo Falini1, Paolo Sportoletti, Maria Paola Martelli

  • 1Institute of Hematology, University of Perugia, Perugia, Italy. faliniem@unipg.itBack to Top

Current Opinion in Oncology
|September 23, 2009
PubMed
Abstract

Insights

Nucleophosmin (NPM1) gene mutations are common in acute myeloid leukemia (AML). This review covers recent advances in NPM1-mutated AML biology, diagnosis, prognosis, and targeted therapies.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Nucleophosmin (NPM1) gene mutations are the most frequent genetic alteration in acute myeloid leukemia (AML), occurring in approximately 30% of cases.
  • These mutations lead to aberrant cytoplasmic expression of nucleophosmin (NPMc+).

Purpose of the Study:

  • To summarize recent advances in the biology, diagnosis, prognosis, and therapy of NPM1-mutated AML.
  • To discuss the implications of NPM1 mutations in myeloid neoplasms.

Main Methods:

  • Review of recent literature on NPM1-mutated AML.
  • Discussion of diagnostic criteria, prognostic factors, and minimal residual disease monitoring.
  • Exploration of molecular mechanisms and targeted therapy development.

Main Results:

  • NPM1-mutated AML is now recognized in the 2008 WHO classification.
  • Recent findings on prognosis and minimal residual disease monitoring impact therapeutic decisions.
  • New insights into nucleophosmin traffic provide a basis for targeted therapies.

Conclusions:

  • Acute myeloid leukemia with mutated NPM1 represents a distinct leukemia entity.
  • It is characterized by unique molecular, pathological, and prognostic features.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...